

WHAT IS CLAIMED IS:

1. GLP-1/GIP/GCG R triple agonist polypeptide compound or salt or solvate thereof with the formula Y-Aib-QGT- α MeF-TSDYSI- α MeL-LDKK(AEEAc-AEEAc- γ Glu-CO(CH₂)₁₈COOH)AQ-Aib-AFIEYLLETGPSSGAPP-Ac3c-S-NH₂ (Compound 1).
2. A pharmaceutical composition comprising an effective amount of the compound or salt or solvate thereof according to claim 1 and pharmaceutically acceptable excipients, diluents, carriers, or excipients.
3. The pharmaceutical composition according to claim 2, characterized in that the pharmaceutical composition is an injection, lyophilized powder, tablet, pill, pastille, soft capsule, hard capsule, granule, powder, solution, suspension or syrup
4. The pharmaceutical composition according to claim 2, characterized in that the pharmaceutical composition is in the form of microcapsule, microspheres, nanoparticle, or liposome.
5. The pharmaceutical composition according to claim 2, characterized in that the pharmaceutical composition is suitable for oral administration, inhalation administration, or parenteral administration.
6. The pharmaceutical composition according to claim 5, characterized in that the pharmaceutical composition is suitable for intraperitoneal, intramuscular, arterial, intravenous, subcutaneous, or intradermal injection administration.
7. The pharmaceutical composition according to claim 2, characterized in that the pharmaceutical composition is suitable for administration at a frequency of at least once a day, once a week, once every two weeks, or once a month.
8. The pharmaceutical composition according to claim 2, characterized in that the pharmaceutical composition is used in combination with at least one therapeutic active substance, and the therapeutic active substance comprises anti-diabetes activator, GIP receptor agonist, GCG receptor agonist or antagonist, GLP-1/GIP receptor agonist, GLP-1/GCG receptor agonist, GIP/GCG receptor agonist, FGF-21 and analogues thereof, cholecystokinin B (CCKB) and analogues thereof PYY (3-36) and analogues thereof, leptin and analogues thereof, calcitonin and analogues thereof, lipid-regulating active drugs, PPAR- α , β , δ Agonists or regulators, antiplatelet aggregation activators, PCSK9 inhibitors, lipase inhibitors, anti-fibrotic or cirrhotic activators, or anti-inflammatory activators.
9. The pharmaceutical composition according to claim 8, characterized in that the anti-diabetes activator comprises insulin, biguanides, sulfonylureas, thiazolidinediones, α -Glucosidase inhibitors, DPP-4 inhibitors, SGLT2 inhibitors, dual SGLT1/SGLT2 inhibitors, GLP-1 receptor agonists, or amylin.
10. GLP-1/GIP/GCG R triple agonist polypeptide compound or salt or solvate thereof according to claim 1 or a pharmaceutical composition according to any of claims 2-9 for use as a medicament.
11. GLP-1/GIP/GCG R triple agonist polypeptide compound or salt or solvate thereof according to claim 1 or a pharmaceutical composition according to any of claims 2-9 for use in the treatment of diabetes, such as type 2 diabetes, obesity, and/or non-alcoholic fatty liver disease.